X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    Nasal Spray Shows Its Effect Against New COVID Variants

    Mid-Point Regulatory Science Strategy Study Published By EMA

    AADC Inadequacy To Be Handled By A Novel Gene Therapy

    New Drug Explored For Epilepsy Gets $3M Funding In Australia

    Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials

    Faster Clinical Trial Nods Planned By The UK To Curb Issues

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    Pharma Drugs Gain From Tardigrade Proteins, Says Research

    U.S. FDA Approves DARZALEX Split-Dosing Regimen

    EMA Keeping A Close Watch On Critical Medicine Shortages

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Pathways Laid Down By The CMS For Drug Price Negotiations

    Efficacy Shown On Cystic Fibrosis Patients In 4-Year Study

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

CTI Biopharma’s Bone Marrow Cancer Drug Stands FDA Approved

Content Team by Content Team
2nd March 2022
in FDA Approvals, News
Sandoz Completes Acquisition of Aspens Japanese Operations

The U.S. Food and Medication Administration authorised CTI BioPharma Corp’s drug for treating adult patients with a kind of bone marrow cancer who also have a low blood platelet count. Vonjo (pacritinib) belongs to a class of anti-inflammatory drugs known as JAK inhibitors, and it will compete with Jakafi from Incyte Corp’s and Bristol-Myers Squibb’s Inrebic, which were authorised for curing myelofibrosis in 2011 and 2019, respectively.

Low platelet count, anaemia, weakness, exhaustion, and often puffiness of the liver and spleen are all symptoms of myelofibrosis, which causes significant damage in the bone marrow and impairs the body’s generation of blood cells. Incyte aims to make $2.3 billion to $2.4 billion in sales in the United States alone, while Inrebic, which Bristol acquired after buying Celgene in 2019, made around $74 million in sales last year.

According to JMP Securities analyst Benjamin Reni, they presently estimate that the company might gain 30% market share, resulting in sales of around $390 million. Reni predicts that CTI BioPharma will charge $260,000 each year for the treatment, a large premium over Jakafi’s $187,000 per annum and a reduction over Inrebic’s $275,184 per year.

They are funded entirely for commercial release, following their loan and royalty agreements with DRI, and they also look forward to delivering VONJO to patients inside 10 days, says CTI BioPharma Chief Executive Officer Adam R. Craig. According to the company, the medicine was approved as a priority, and the company got $60 million from DRI Healthcare Trust because of that.

In late-stage research, 29 percent of patients with acute thrombocytopenia who were administered twice daily with CTI BioPharma’s medication saw a decrease in spleen size, compared to 3 percent of patients who received the best available treatment, including Jakafi. In November, the US Food and Drug Administration put off its decision on the medicines for three months so that it could look at more data from the company.

Previous Post

COPD Teams Up With Ena On Antiviral Nasal Spray For COVID

Next Post

UK Manufacturing And Health Research Gets £260 Million Boost

Related Posts

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Drugs Gain From Tardigrade Proteins, Says Research
Drug Development

Pharma Drugs Gain From Tardigrade Proteins, Says Research

22nd March 2023
Next Post
WHO Puts In Place Another Training Hub For Biomanufacturing

UK Manufacturing And Health Research Gets £260 Million Boost

Latest News

Drug Development

Nasal Spray Shows Its Effect Against New COVID Variants

27th March 2023
FDA Approvals

Mid-Point Regulatory Science Strategy Study Published By EMA

27th March 2023
Drug Development

AADC Inadequacy To Be Handled By A Novel Gene Therapy

24th March 2023
Drug Development

New Drug Explored For Epilepsy Gets $3M Funding In Australia

23rd March 2023
Care Access Research Launches Alliance to Provide Infrastructure for COVID-19 Trials
Clinical Trials

Faster Clinical Trial Nods Planned By The UK To Curb Issues

22nd March 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In